<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588935</url>
  </required_header>
  <id_info>
    <org_study_id>20192755</org_study_id>
    <nct_id>NCT04588935</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer</brief_title>
  <official_title>To Develop and Implement a Method for Medical Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Institution &quot;Republican Scientific and Practical Center&quot; Cardiology, Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Institution &quot;Republican Scientific and Practical Center&quot; Cardiology, Belarus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity&#xD;
      against the background of complex treatment of patients with primary resectable breast cancer&#xD;
      to reduce the risk of cardiovascular complications&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of the study: to develop a method of medical prevention of cardiovascular diseases&#xD;
      caused by cardiotoxicity against the background of complex treatment of patients with primary&#xD;
      resectable breast cancer to reduce the risk of cardiovascular complications&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>development of cardiovascular diseases and complications</measure>
    <time_frame>4 years</time_frame>
    <description>hypertension, cardiomyopathy, arrhythmia's, myocardial infarction, heart failure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Women With Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol; Perindopril;</intervention_name>
    <description>based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Bisoprolol; Perindopril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women with breast cancer, with a morphologically confirmed diagnosis before the&#xD;
             appointment of anticancer therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of other oncological diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sergey Chernyak</last_name>
    <phone>+375296322661</phone>
    <email>Lapydus@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientific and Practice Center of Cardiology</name>
      <address>
        <city>Minsk</city>
        <zip>220000</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Pavlova</last_name>
      <email>olga.s_pavlova@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Sergey Charnyak</last_name>
      <phone>+375296322661</phone>
      <email>Lapydus@yandex.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Institution &quot;Republican Scientific and Practical Center&quot; Cardiology, Belarus</investigator_affiliation>
    <investigator_full_name>Dr. Chernyak Sergey</investigator_full_name>
    <investigator_title>Researcher, Hypertension Laboratory Republican Scientific and Clinical Cardiology Center Republic of Belarus, Belarus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

